Related references
Note: Only part of the references are listed.Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability
Paolo Giuffrida et al.
MODERN PATHOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes
Jordan Roberts et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Small Bowel Adenocarcinoma Version 1.2020
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Integrated genomic profiling expands clinical options for patients with cancer
Nike Beaubier et al.
NATURE BIOTECHNOLOGY (2019)
Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
Pat Gulhati et al.
ONCOLOGIST (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer
M. J. Overman et al.
ANNALS OF ONCOLOGY (2018)
Bevacizumab Combined With Capecitabine and Oxaliplatin in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater: A Single-Center, Open-Label, Phase 2 Study
Pat Gulhati et al.
CANCER (2017)
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
Michel Ducreux et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
Takahiro Horimatsu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Genomic Profiling of Small-Bowel Adenocarcinoma
Alexa B. Schrock et al.
JAMA ONCOLOGY (2017)
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
Ramya Thota et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma
Robert R. McWilliams et al.
CANCER (2017)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
Marisa Dolled-Filhart et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Stromal characterization of small bowel adenocarcinomas
Katrina Pedersen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA)
Katrina Pedersen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment
Thomas Aparicio et al.
DIGESTIVE AND LIVER DISEASE (2014)
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma
Anais Laforest et al.
EUROPEAN JOURNAL OF CANCER (2014)
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma
Xiao Jun Xiang et al.
ANTI-CANCER DRUGS (2012)
Second-Line Chemotherapy With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI Regimen) in Patients With Advanced Small Bowel Adenocarcinoma After Failure of First-Line Platinum-Based Chemotherapy A Multicenter AGEO Study
Aziz Zaanan et al.
CANCER (2011)
Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas
H Bläker et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Share Paper
